Celerity Pharmaceuticals uses Biocon Biologics’ insulin drug substance to develop the product
Through this consortium, Lonza will collaborate with other industry leaders to advance the research and development of inhalation technologies
No new studies have been requested
World-leading companies, as well as small innovative research groups, regularly partner with Medanex for their outstanding cardiovascular services and timely, efficacious study outcomes.
A novel second-generation approach to achieve a safe, durable, and stable transgene expression to overcome the challenges of factor VIII replacement therapies
AbbVie to present 30 abstracts demonstrating its leadership in neuroscience, including continued migraine treatment research across the spectrum of the disease, commitment to patients with advanced Parkinson's disease, and new studies in spasticity and cervical dystonia
The amalgamation will integrate business operations and provide impetus to the existing portfolio of Alembic
50 µg dose approved for all adults over 50 years of age and immunocompromised adults over 18 years of age
In May 2021, Daiichi Sankyo had submitted a supplemental new drug application (sNDA) for Tarlige tablets based on results from a phase 3 trial in patients with CNP
Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months
Subscribe To Our Newsletter & Stay Updated
